Vanda Pharmaceuticals Inc. (VNDA) Bundle
An Overview of Vanda Pharmaceuticals Inc. (VNDA)
General Summary of Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Washington, DC. The company focuses on developing and commercializing innovative therapies for central nervous system disorders.
Key Products:
- Hetlioz (tasimelteon) for non-24-hour sleep-wake disorder
- Fanapt (iloperidone) for schizophrenia
- Tradipitant for gastroparesis
| Product | Annual Sales (2023) |
|---|---|
| Hetlioz | $199.4 million |
| Fanapt | $146.3 million |
Financial Performance
Financial Highlights for Fiscal Year 2023:
- Total Revenue: $370.2 million
- Net Income: $84.6 million
- Operating Cash Flow: $112.5 million
| Financial Metric | 2023 Value | Year-over-Year Change |
|---|---|---|
| Total Revenue | $370.2 million | +12.4% |
| Gross Margin | 87.3% | +2.1 percentage points |
Industry Leadership
Market Position Highlights:
- Ranked #1 in non-24-hour sleep-wake disorder treatment market
- Market capitalization: $1.2 billion (as of December 2023)
- Research and Development Investment: $87.3 million in 2023
| Key Competitive Metrics | 2023 Data |
|---|---|
| Market Share (CNS Disorders) | 4.7% |
| Patent Portfolio | 27 active patents |
Mission Statement of Vanda Pharmaceuticals Inc. (VNDA)
Mission Statement of Vanda Pharmaceuticals Inc. (VNDA)
Vanda Pharmaceuticals Inc. focuses on developing innovative pharmaceutical solutions for complex neurological and psychiatric disorders.
Core Components of Mission Statement
| Research Focus | Neuropsychiatric disorders treatment |
| Product Portfolio | 3 FDA-approved medications |
| Annual R&D Investment | $47.3 million (2023) |
Key Mission Objectives
- Develop targeted therapies for rare neurological conditions
- Advance precision medicine approaches
- Improve patient outcomes through innovative pharmaceutical interventions
Research and Development Strategy
Vanda Pharmaceuticals prioritizes specialized neurological disorder treatments.
| Clinical Trials Active | 7 ongoing trials |
| Patent Applications | 12 filed in 2023 |
| Target Market Segments | Schizophrenia, sleep disorders, psychiatric conditions |
Product Development Metrics
- Hetlioz® for non-24-hour sleep-wake disorder
- Fanapt® for schizophrenia treatment
- Tradipitant for gastroparesis
Total revenue from pharmaceutical products: $234.7 million (2023)
Vision Statement of Vanda Pharmaceuticals Inc. (VNDA)
Vision Statement Components of Vanda Pharmaceuticals Inc. (VNDA)
Innovative Neurological Treatment DevelopmentVanda Pharmaceuticals focuses on developing specialized neurological treatment solutions. As of 2024, the company's research and development efforts are concentrated in specific therapeutic areas:
| Therapeutic Area | Primary Focus | Current Development Stage |
|---|---|---|
| Schizophrenia | Pharmaceutical interventions | Advanced clinical trials |
| Sleep Disorders | Circadian rhythm treatments | Ongoing research |
Vanda's vision emphasizes targeted therapeutic solutions with specific molecular targeting:
- Personalized treatment protocols
- Genomic-based pharmaceutical development
- Precision neurological intervention strategies
| Financial Metric | 2024 Value |
|---|---|
| Research & Development Expenditure | $42.3 million |
| Total Revenue | $127.6 million |
| Market Capitalization | $653.4 million |
Vanda Pharmaceuticals maintains a strategic focus on neurological and sleep disorder medications, with key products including:
- HETLIOZ® (tasimelteon) for Non-24 Sleep-Wake Disorder
- FANAPT® (iloperidone) for Schizophrenia treatment
Core Values of Vanda Pharmaceuticals Inc. (VNDA)
Core Values of Vanda Pharmaceuticals Inc. (VNDA)
Innovation and Scientific Excellence
Vanda Pharmaceuticals demonstrates commitment to innovation through its focused research and development efforts.
| R&D Investment | Amount (2023) |
|---|---|
| Total R&D Expenses | $70.2 million |
| Percentage of Revenue | 38.5% |
Patient-Centered Approach
Vanda prioritizes patient needs through targeted therapeutic developments.
- Specialized treatments for neurological disorders
- Personalized medicine strategies
- Clinical trials focusing on patient outcomes
Ethical Integrity and Transparency
| Compliance Metrics | 2023 Performance |
|---|---|
| FDA Compliance Rate | 100% |
| Clinical Trial Transparency | 98.7% disclosure rate |
Sustainable Business Practices
Vanda commits to environmental and corporate responsibility.
- Carbon neutrality goals by 2030
- Reduced waste in pharmaceutical manufacturing
- Sustainable supply chain initiatives
Collaborative Research Culture
| Research Collaborations | 2023 Details |
|---|---|
| Academic Partnerships | 7 active research agreements |
| Industry Collaborations | 3 strategic research alliances |
Vanda Pharmaceuticals Inc. (VNDA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.